All In Biotech

Drug Trial Radar · NCT03860272

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

499

Actual

Start

Mar 20, 2019

Primary completion

Jan 13, 2025

Study completion Dec 2027

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Mar 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy and in combination with balstilimab.

Conditions

  • Advanced Cancer
  • Angiosarcoma
  • Colorectal Cancer Without Liver Metastases
  • Endometrial Cancer
  • Fibrolamellar Carcinoma
  • Non-small-cell Lung Cancer
  • Ovarian Cancer
  • Prostate Cancer

Interventions

  • BotensilimabDrug

    An Fc-engineered anti-CTLA-4 monoclonal antibody

  • BalstilimabDrug

    A fully human monoclonal anti-PD-1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Of Treatment-emergent Adverse Events (TEAEs)Time frame: First dose through 90 days following last study dose (up to 2 years)
  2. DLT Of BotensilimabTime frame: First 28 days of treatment
  3. RP2D Of BotensilimabTime frame: First dose through 90 days following last study dose

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate

    Los Angeles, California

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Santa Monica Hematology Oncology

    Los Angeles, California

  • Saint John's Cancer Institute

    Santa Monica, California

  • University of Colorado

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Providence Portland Cancer Center

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Royal Marsden Hospital NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.